Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the FALCON study is to evaluate the efficacy of KL1333 on selected
disease manifestations of primary mitochondrial disease (PMD) following 48 weeks of
treatment. This objective involves evaluating the efficacy of KL1333 versus placebo on
fatigue symptoms and impacts on daily living as well as on functional lower extremity
strength and endurance. Additionally, the study evaluates the safety and tolerability of
KL1333.